CircRNA ÇÕ¼º ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Á¦Ç° ¹× ¼ºñ½ºº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
CircRNA Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Reagents & Kits), By Application (Therapeutics Development), By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1654444
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 01¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 120 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
CircRNA ÇÕ¼º ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°èÀÇ CircRNA ÇÕ¼º ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 4¾ï 4,250¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2025-2030³â°£ ¿¬Æò±Õ 15.88%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼øÈ¯ RNA ÇÕ¼º »ê¾÷Àº ¼øÈ¯ RNAÀÇ Ä¡·á °¡´É¼ºÀ» °Á¶ÇÏ´Â Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ³ë·Â¿¡ ÈûÀÔ¾î Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù Nature Reviews Genetics¿¡ °ÔÀçµÈ ¼½Ã¿À °úÇÐÀÚµéÀÇ Á¾ÇÕÀûÀÎ ÃÑÆòÀº Çâ»óµÈ ¾ÈÁ¤¼º°ú ¿ì¼öÇÑ ¸é¿ªÇÐÀû ÇÁ·ÎÆÄÀÏ µî CircRNAÀÇ °íÀ¯ÇÑ Æ¯¼ºÀ» °Á¶Çϸç, °¨¿°¼º Áúȯ, CAR-T Ä¡·á, À¯ÀüÀÚ Ä¡·á µî ´Ù¾çÇÑ Ä¡·á¿ëµµ¿¡ ´ëÇÑ À¯¸ÁÇÑ Èĺ¸¹°ÁúÀÓÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù. µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Ã¥Àº CircRNA Ä¡·áÀÇ ÇöÀç ÁøÀüÀ» °Á¶ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ÀÌ ºÐ¾ßÀÇ ±âȸ¿Í °úÁ¦¸¦ ¹àÇô ´õ ¸¹Àº ÅõÀÚ¿Í Å½±¸¸¦ Àå·ÁÇϰí ÀÖ½À´Ï´Ù.
±â¾÷ °£ Àü·«Àû Á¦ÈÞµµ ½ÃÀåÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 1¿ù Circio´Â 4basebio¿Í Á¦ÈÞÇÏ¿© À¯ÀüÀÚ ÀÇ·á ¹× ¹é½Å¿ë ÇÕ¼º circVec DNA º¤ÅÍÀÇ °³¹ß ¹× Å×½ºÆ®¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. À̹ø Á¦ÈÞ´Â CircioÀÇ circVec ¼øÈ¯ RNA ¹ßÇö ½Ã½ºÅÛ°ú 4basebioÀÇ µ¶ÀÚÀûÀÎ ÇÕ¼º DNA Æ÷¸Ë°ú µ¶ÀÚÀûÀÎ ³ª³ëÀÔÀÚ Àü´Þ Ç÷§ÆûÀÎ Hermes¸¦ °áÇÕÇÏ¿© °·ÂÇÑ Ä¡·á Á¶ÇÕÀ» âÃâÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦ÈÞ´Â ¹Ì·¡ÀÇ ÇÕ¼º DNA À¯ÀüÀÚ Ä¡·á¸¦ À§ÇÑ ³»±¸¼º ÀÖ°í ¹Ýº¹ÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Â ºñ¹ÙÀÌ·¯½º¼º Ç÷§ÆûÀ» °³¹ßÇÏ´Â µ¥ ÀÖÀ¸¸ç, Áß¿äÇÑ Àǹ̸¦ °®½À´Ï´Ù.
CircRNA »ý»ê ±â¼úÀÇ Çõ½ÅÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 8¿ù Abogen Biosciences´Â Cis-SystemÀ̶ó´Â ¼øÈ¯ RNA »ý»êÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ¸Å¿ì È¿À²ÀûÀÎ RNA ¼øÈ¯È ½Ã½ºÇöóÀÌ½Ì ½Ã½ºÅÛ °³¹ßÀ» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ÀÌ µ¶ÀÚÀûÀÎ ½Ã½ºÅÛÀº ¼¼°è ÁöÀûÀç»ê±ÇÀ» °¡Áö°í ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó ±âÁ¸ ¹æ¹ýº¸´Ù °³¼±µÇ¾î CircRNA »ý»êÀÇ È¿À²¼º°ú È®À强À» Çâ»ó½Ãų ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû Áøº¸´Â CircRNA¸¦ Ä¡·á ¹× ¹é½Å¿¡ ±¤¹üÀ§ÇÏ°Ô Àû¿ëÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇϸç, ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
CircRNA ÇÕ¼º ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ½Ã¾à ¹× ŰƮ ºÎ¹®Àº 2024³â 47.29%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¿¬±¸ ¹× Ä¡·á °³¹ß ºÐ¾ß¿¡¼ CircRNA ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ¾ÈÁ¤ÀûÀÌ°í ±â´ÉÀûÀÎ CircRNA¸¦ »ý»êÇϱâ À§ÇØ È¿À²ÀûÀÎ ¼øÈ¯È °øÁ¤, º¤ÅÍ ±¸Ãà, Á¤Á¦¸¦ À§ÇÑ °íǰÁú ½Ã¾à ¹× ŰƮ°¡ ÇÊ¿äÇÕ´Ï´Ù.
- 2024³â¿¡´Â CircRNA¿¡ ¸Â°Ô Á¶Á¤µÈ ÁöÁú ³ª³ëÀÔÀÚ(LNPs)¿Í °°Àº Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î È¿À²ÀûÀ̰í Á¤È®ÇÑ Ä¡·á Àû¿ëÀÌ °¡´ÉÇØÁü¿¡ µû¶ó Ä¡·á °³¹ßÀÌ °¡Àå Å« ¸ÅÃâ ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. curRNA Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá ÀüÀÓ»ó ¹× ÀÓ»ó ¿¬±¸ Áõ°¡´Â ÀÌ ½ÃÀåÀÌ Çö´ë ÀǷḦ º¯È½Ãų ¼ö ÀÖ´Ù´Â °ÍÀ» ÀÔÁõÇÕ´Ï´Ù. Çö´ëÀÇÇÐÀ» º¯È½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» ÀÔÁõÇϰí ÀÖ½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ ºÎ¹®ÀÌ 2024³â 59.55%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº Çõ½ÅÀûÀÎ Ä¡·á¹ý°ú ¹é½Å¿¡ ´ëÇÑ ÀáÀç·ÂÀ» Ȱ¿ëÇÏ¿© CircRNA ÇÕ¼º »ê¾÷ÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
- ºÏ¹Ì´Â 2024³â 45.12%ÀÇ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº RNA ±â¹Ý ¿¬±¸¿¡ ´ëÇÑ È°¹ßÇÑ ÅõÀÚ, »ý¸í°øÇÐ ¹× Á¦¾à ±â¾÷ÀÇ Á¸Àç°¨, RNA Ä¡·á ¹× ¹é½Å¿¡ ´ëÇÑ °ü½É Áõ°¡, NIH º¸Á¶±Ý°ú °°Àº Á¤ºÎ ÀÚ±Ý ¹× Çмú °øµ¿ ¿¬±¸·Î ÀÎÇØ ÀÌ ºÎ¹®ÀÇ ¹ßÀüÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ª¿¡´Â ÀÓ»ó °Ë»ç ¹× ÷´Ü ±â¼úÀ» À§ÇÑ ÀÎÇÁ¶ó°¡ ±¸ÃàµÇ¾î ÀÖÀ¸¸ç, CircRNA Ç÷§ÆûÀÇ Ã¤ÅÃÀ» °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå °³¿ä
Á¦3Àå CircRNA ÇÕ¼º ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- ¸ð½ÃÀå Àü¸Á
- °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- »ê¾÷ ºÐ¼® Åø
- Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå CircRNA ÇÕ¼º ½ÃÀå : Á¦Ç°¡¤¼ºñ½ºº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- Á¦Ç°¡¤¼ºñ½º ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ CircRNA ÇÕ¼º ½ÃÀåÀÇ Á¦Ç°¡¤¼ºñ½ºÀÇ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ CircRNA ÇÕ¼º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°¡¤¼ºñ½ºº°, 2018-2030³â
- ½Ã¾à°ú ŰƮ
- ±â±â
- ¼ºñ½º
Á¦5Àå CircRNA ÇÕ¼º ½ÃÀå : ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ CircRNA ÇÕ¼º ½ÃÀåÀÇ ¿ëµµ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ CircRNA ÇÕ¼º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
- Ä¡·á °³¹ß
- Drug Discovery
- ±âŸ
Á¦6Àå CircRNA ÇÕ¼º ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ CircRNA ÇÕ¼º ½ÃÀåÀÇ ÃÖÁ¾ ¿ëµµÀÇ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ CircRNA ÇÕ¼º ½ÃÀåÀÇ ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
- Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
- Çмú¿¬±¸±â°ü
- ±âŸ
Á¦7Àå CircRNA ÇÕ¼º ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
- Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, 2018-2030³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- ű¹
- Çѱ¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
- Âü¿© ±â¾÷
- ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®, 2024³â
- Âü¿© ±â¾÷ °³¿ä
- LGC Biosearch Technologies
- Creative Biogene
- SBS Genetech
- Applied Biological Materials Inc
- GenScript
- Amerigo Scientific
- BOC Sciences
- GeneCopoeia, Inc.
- Guangzhou Geneseed BIoTech. Co., Ltd.
- Creative Biolabs
KSA
¿µ¹® ¸ñÂ÷
CircRNA Synthesis Market Growth & Trends:
The global circRNA synthesis market size is anticipated to reach USD 442.5 million by 2030 and grow at a CAGR of 15.88% from 2025 to 2030 during the forecast period, according to a new report by Grand View Research, Inc. The circRNA synthesis industry is experiencing significant growth, driven by ongoing research and development efforts that highlight the therapeutic potential of circular RNAs. A recent comprehensive review published in Nature Reviews Genetics by Circio scientists underscores the unique properties of circRNAs, such as enhanced stability and superior immunological profiles, which make them promising candidates for various therapeutic applications, including infectious diseases, CAR-T therapy, and gene therapy. This publication not only emphasizes the current advancements in circRNA therapeutics but also identifies opportunities and challenges in the field, thereby encouraging further investment and exploration.
Strategic collaborations between companies are also propelling the market forward. For instance, in January 2024, Circio has partnered with 4basebio to develop and test synthetic circVec DNA vectors for genetic medicine and vaccines. This partnership aims to combine Circio's circVec circular RNA expression system with 4basebio's proprietary synthetic DNA formats and unique nanoparticle delivery platform, Hermes, to create a powerful therapeutic combination. Such alliances are instrumental in advancing the development of durable, repeat-dosable, non-viral platforms for future synthetic DNA gene therapies.
Innovations in circRNA production technologies are further driving market expansion. For instance, in August 2024, Abogen Biosciences, has announced the development of a highly efficient RNA circularization cis-splicing system, referred to as the Cis-System, which enables the production of circular RNA. This proprietary system not only holds global intellectual property rights but also offers improvements over existing methods, potentially enhancing the efficiency and scalability of circRNA production. Such technological advancements are crucial for the broader application of circRNA in therapeutics and vaccines, thereby fueling market growth.
CircRNA Synthesis Market Report Highlights:
- The reagents and kits segment captured the largest revenue share of 47.29% in 2024. The increasing adoption of circRNA technologies in research and therapeutic development. Researchers require high-quality reagents and kits for efficient circularization processes, vector construction, and purification to produce stable and functional circRNAs.
- In 2024, therapeutics development dominated the market with the largest revenue share, driven by the advancements in delivery systems, such as lipid nanoparticles (LNPs) tailored for circRNA, are enabling efficient and precise therapeutic applications. The rising number of preclinical and clinical studies focused on circRNA therapeutics underscores the market's potential to transform modern medicine.
- By end use, the pharmaceutical and biotechnology companies segment captured the largest revenue share of 59.55% in 2024. The market is driving growth in the circRNA synthesis industry by leveraging its potential for innovative therapies and vaccines.
- The North American region dominated the market share of 45.12% in 2024. The market is driven by robust investments in RNA-based research, a strong presence of biotech and pharmaceutical companies, and growing interest in RNA therapeutics and vaccines. Government funding, such as NIH grants, and academic collaborations further support advancements in the field. Additionally, the region's established infrastructure for clinical trials and cutting-edge technologies accelerates the adoption of circRNA platforms.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Product & Service
- 1.2.2. Application
- 1.2.3. End Use
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. CircRNA Synthesis Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Advancements in RNA-Based Therapeutics
- 3.2.1.2. Increased Research Investment
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Technical Challenges in Production and Delivery
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. CircRNA Synthesis Market: Product & Services Estimates & Trend Analysis
- 4.1. Product & Service Segment Dashboard
- 4.2. Global CircRNA Synthesis Market Product & Service Movement Analysis
- 4.3. Global CircRNA Synthesis Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
- 4.4. Reagents & Kits
- 4.4.1. Reagents & Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Instruments
- 4.5.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Services
- 4.6.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. CircRNA Synthesis Market: Application Estimates & Trend Analysis
- 5.1. Application Segment Dashboard
- 5.2. Global CircRNA Synthesis Market Application Movement Analysis
- 5.3. Global CircRNA Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Therapeutics Development
- 5.4.1. Therapeutics Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Drug Discovery
- 5.5.1. Drug Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Other Applications
- 5.6.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. CircRNA Synthesis Market: End Use Estimates & Trend Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Global CircRNA Synthesis Market End Use Movement Analysis
- 6.3. Global CircRNA Synthesis Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 6.4. Pharmaceutical & Biotechnology Companies
- 6.4.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Academic & Research Institutes
- 6.5.1. Academic & Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. CircRNA Synthesis Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 7.4. North America
- 7.4.1. North America CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. U.S. CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Canada CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Mexico CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. UK CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Germany CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. France CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Italy CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Spain CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Denmark CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Sweden CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Competitive Scenario
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Norway CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Japan CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. China CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. India CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Australia CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Thailand CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. South Korea
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competitive Scenario
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. South Korea CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Brazil CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Argentina CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. MEA CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. South Africa CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Saudi Arabia CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. UAE CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Competitive Scenario
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Kuwait CircRNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Categorization
- 8.2. Company Market Position Analysis, 2024
- 8.3. Participant's Overview
- 8.3.1. LGC Biosearch Technologies
- 8.3.1.1. Participant's Overview
- 8.3.1.2. Financial Performance
- 8.3.1.3. Product/Service Benchmarking
- 8.3.1.4. Strategic Initiatives
- 8.3.2. Creative Biogene
- 8.3.2.1. Participant's Overview
- 8.3.2.2. Financial Performance
- 8.3.2.3. Product/Service Benchmarking
- 8.3.2.4. Strategic Initiatives
- 8.3.3. SBS Genetech
- 8.3.3.1. Participant's Overview
- 8.3.3.2. Financial Performance
- 8.3.3.3. Product/Service Benchmarking
- 8.3.3.4. Strategic Initiatives
- 8.3.4. Applied Biological Materials Inc
- 8.3.4.1. Participant's Overview
- 8.3.4.2. Financial Performance
- 8.3.4.3. Product/Service Benchmarking
- 8.3.4.4. Strategic Initiatives
- 8.3.5. GenScript
- 8.3.5.1. Participant's Overview
- 8.3.5.2. Financial Performance
- 8.3.5.3. Product/Service Benchmarking
- 8.3.5.4. Strategic Initiatives
- 8.3.6. Amerigo Scientific
- 8.3.6.1. Participant's Overview
- 8.3.6.2. Financial Performance
- 8.3.6.3. Product/Service Benchmarking
- 8.3.6.4. Strategic Initiatives
- 8.3.7. BOC Sciences
- 8.3.7.1. Participant's Overview
- 8.3.7.2. Financial Performance
- 8.3.7.3. Product/Service Benchmarking
- 8.3.7.4. Strategic Initiatives
- 8.3.8. GeneCopoeia, Inc.
- 8.3.8.1. Participant's Overview
- 8.3.8.2. Financial Performance
- 8.3.8.3. Product/Service Benchmarking
- 8.3.8.4. Strategic Initiatives
- 8.3.9. Guangzhou Geneseed Biotech. Co., Ltd.
- 8.3.9.1. Participant's Overview
- 8.3.9.2. Financial Performance
- 8.3.9.3. Product/Service Benchmarking
- 8.3.9.4. Strategic Initiatives
- 8.3.10. Creative Biolabs
- 8.3.10.1. Participant's Overview
- 8.3.10.2. Financial Performance
- 8.3.10.3. Product/Service Benchmarking
- 8.3.10.4. Strategic Initiatives
°ü·ÃÀÚ·á